Patents by Inventor Frank Fang

Frank Fang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210324084
    Abstract: A pharmaceutical composition for use in treating hepatitis B virus (HBV) infection includes an effective amount of an antibody against CD11b or a binding fragment thereof. A method for treating hepatitis B virus infection includes administering to a subject in need thereof an antibody against CD11b. Anti-CD11b antibody binding to CD11b may trigger immunostimulatory responses, as evidenced by the following observations: increased surface expression of MHC II and CD86 in CD11b+ peripheral blood mononuclear cells (PBMCs); suppressed level of hepatitis B surface antigen (HBsAg) and HBV DNA in the blood; and accelerated clearance of HBV from liver.
    Type: Application
    Filed: August 9, 2019
    Publication date: October 21, 2021
    Applicant: Ascendo Biotechnology, Inc.
    Inventors: Yen-Ta LU, Ping-Yen HUANG, Chia-Ming CHANG, I-Fang TSAI, Frank Wen-Chi LEE, Huei-Ling CHANG
  • Publication number: 20210276939
    Abstract: The invention relates to compounds of formula (I) where R1, R2, R3, R4 are each independently selected from —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl, —(C3-C20)-heteroaryl; at least one of the R1, R2, R3, R4 radicals is a —(C3-C20)-heteroaryl radical; and R1, R2, R3, R4, if they are —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl or —(C3-C20)-heteroaryl, may each independently be substituted by one or more substituents selected from —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —O—(C1-C12)-alkyl, —O—(C1-C12)-alkyl-(C6-C20)-aryl, —O—(C3-C12)-cycloalkyl, —S—(C1-C12)-alkyl, —S—(C3-C12)-cycloalkyl, —COO—(C1-C12)-alkyl, —COO—(C3-C12)-cycloalkyl, —CONH—(C1-C12)-alkyl, —CONH—(C3-C12)-cycloalkyl, —CO—(C1-C12)-alkyl, —CO—(C3-C12)-cycloalkyl, —N—[(C1-C12)-alkyl]2, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, —(C3-C20)-heteroaryl, —(C3-C20)-heteroaryl-(C1-C12)-alkyl, —(C3-C20)-hetero
    Type: Application
    Filed: May 21, 2021
    Publication date: September 9, 2021
    Applicant: EVONIK OPERATIONS GMBH
    Inventors: Kaiwu DONG, Xiangjie FANG, Helfried NEUMANN, Ralf JACKSTELL, Matthias BELLER, Robert FRANKE, Dieter HESS, Katrin Marie DYBALLA, Dirk FRIDAG, Frank GEILEN
  • Publication number: 20210205348
    Abstract: Provided herein are methods for the treatment of bladder cancer.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 8, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Patent number: 11028119
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 8, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis
  • Patent number: 10941148
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: March 9, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Publication number: 20200299321
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 4, 2020
    Publication date: September 24, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Patent number: 10719057
    Abstract: A method for suppressing a non-periodic random event in a proximity system includes: receiving an output signal generated by a proximity sensor in the proximity system and monitoring at least a magnitude of the output signal; determining whether a spike having a magnitude exceeding a prescribed threshold value has occurred in the output signal; when a spike in the output signal is detected, setting an output of the proximity system to a prescribed level for a prescribed duration of time; when the prescribed duration of time has elapsed, determining whether the output signal meets one or more prescribed criteria indicative of a shutdown condition; when it is determined that the output signal meets the prescribed criteria, setting the output of the proximity system to a level exceeding an alarm threshold; and when it is determined that the output signal fails to meet at least one of the prescribed criteria, releasing suppression of the output of the proximity system.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: July 21, 2020
    Assignee: METRIX INSTRUMENT CO., LP
    Inventors: Frank Fang, Everett Jesse, Matthew Webster
  • Publication number: 20200123189
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 23, 2020
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis
  • Patent number: 10618930
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 14, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Publication number: 20200055883
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 16, 2018
    Publication date: February 20, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Patent number: 10526362
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: January 7, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis
  • Publication number: 20190345192
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 15, 2019
    Publication date: November 14, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Publication number: 20190315754
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: April 23, 2019
    Publication date: October 17, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Publication number: 20190179281
    Abstract: A method for suppressing a non-periodic random event in a proximity system includes: receiving an output signal generated by a proximity sensor in the proximity system and monitoring at least a magnitude of the output signal; determining whether a spike having a magnitude exceeding a prescribed threshold value has occurred in the output signal; when a spike in the output signal is detected, setting an output of the proximity system to a prescribed level for a prescribed duration of time; when the prescribed duration of time has elapsed, determining whether the output signal meets one or more prescribed criteria indicative of a shutdown condition; when it is determined that the output signal meets the prescribed criteria, setting the output of the proximity system to a level exceeding an alarm threshold; and when it is determined that the output signal fails to meet at least one of the prescribed criteria, releasing suppression of the output of the proximity system.
    Type: Application
    Filed: December 7, 2018
    Publication date: June 13, 2019
    Inventors: Frank Fang, Everett Jesse, Matthew Webster
  • Patent number: 10316040
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 11, 2019
    Assignee: Eisai R&D Management Co., LTD.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Patent number: 10246480
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: April 2, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-Wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Publication number: 20180305362
    Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Wanjun Zheng, Xiaojie Zhu, Hong Du, Maarten Postema, Yimin Jiang, Jing Li, Robert Yu, Hyeong-wook Choi, Jaemoon Lee, Frank Fang, Daniel Custar
  • Publication number: 20180237468
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 17, 2018
    Publication date: August 23, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Publication number: 20180072768
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Application
    Filed: November 15, 2017
    Publication date: March 15, 2018
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis
  • Patent number: 9834576
    Abstract: The present invention relates to methods and intermediates for synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine compounds.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: December 5, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hyeong-wook Choi, Steven Mathieu, Frank Fang, Bryan Matthew Lewis